Pragma Pharmaceuticals, LLC Announces Acquisition of Keflex®

NEW YORK–(BUSINESS WIRE)–Pragma Pharmaceuticals is pleased to announce that it has finalized the
acquisition of the Keflex product line from Shionogi Inc.


Pragma is working toward launching later this month with Fera
Pharmaceuticals managing the sales and marketing of the product.

Keflex is the gold standard in the cephalosporin class of antibiotics.
Cephalexin is among the most widely used anti-infectives in the US, with
over 22 million prescriptions dispensed annually.

About Keflex

Keflex (cephalexin capsules, USP) is a first-generation cephalosporin
antibiotic shown to be active against strains of both gram-positive and
gram-negative aerobes in vitro and in clinical infections. Keflex is
indicated for treatment of the following infections: respiratory tract
infections, otitis media, skin and skin structure infections, bone
infections, and genitourinary tract infections. More information on
Keflex and full prescribing information are available at www.ferapharma.com.

Contacts

Pragma Pharmaceuticals
Louis B. DellaFera, Pharm. D., 516-277-1450
Louis@pragmapharma.com